DBV Technologies (NASDAQ:DBVT) Shares Gap Up – What’s Next?

DBV Technologies S.A. (NASDAQ:DBVT)’s stock price gapped up prior to trading on Friday . The stock had previously closed at $20.06, but opened at $21.49. DBV Technologies shares last traded at $20.80, with a volume of 110,344 shares trading hands.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Cantor Fitzgerald set a $48.00 price target on DBV Technologies in a research report on Wednesday, December 17th. HC Wainwright set a $40.00 price objective on shares of DBV Technologies in a research note on Thursday, December 18th. Weiss Ratings restated a “sell (e+)” rating on shares of DBV Technologies in a research report on Monday, December 29th. Guggenheim reaffirmed a “buy” rating and issued a $51.00 target price (up from $35.00) on shares of DBV Technologies in a report on Wednesday, December 17th. Finally, Wall Street Zen upgraded shares of DBV Technologies from a “sell” rating to a “hold” rating in a research report on Sunday, February 8th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $38.25.

DBV Technologies Trading Up 1.7%

The firm has a market capitalization of $1.14 billion, a PE ratio of -3.94 and a beta of -0.97. The stock’s 50 day moving average price is $21.13 and its two-hundred day moving average price is $16.42.

Insiders Place Their Bets

In other news, major shareholder Bpifrance Epic sold 2,076,990 shares of the business’s stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $4.85, for a total value of $10,073,401.50. Following the completion of the transaction, the insider directly owned 8,595,472 shares of the company’s stock, valued at $41,688,039.20. The trade was a 19.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders sold a total of 3,369,627 shares of company stock worth $15,489,908 over the last ninety days. Company insiders own 1.44% of the company’s stock.

Institutional Trading of DBV Technologies

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DBVT. Allworth Financial LP acquired a new position in DBV Technologies in the 4th quarter valued at about $32,000. Royal Bank of Canada acquired a new stake in shares of DBV Technologies during the 4th quarter worth about $34,000. GAMMA Investing LLC grew its holdings in shares of DBV Technologies by 38.4% during the fourth quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock worth $51,000 after buying an additional 744 shares in the last quarter. New York State Common Retirement Fund acquired a new position in shares of DBV Technologies in the third quarter valued at approximately $34,000. Finally, Truvestments Capital LLC lifted its stake in shares of DBV Technologies by 71.3% during the fourth quarter. Truvestments Capital LLC now owns 3,892 shares of the company’s stock valued at $75,000 after buying an additional 1,620 shares during the period. Hedge funds and other institutional investors own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.